title: Inhibitory effect of roxithromycin on the local levels of bone-resorbing cytokines in an experimental model of murine osteomyelitis.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the inhibitory effect of roxithromycin on the production of interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha (TNF-alpha) in a murine tibial osteomyelitis model using Staphylococcus aureus.
  
  
  METHODS
  Cytokine levels in supernatants derived from bone homogenates were measured by enzyme-linked immunosorbent assay for 28 days, after oral administration of roxithromycin at 5 mg/kg/day.
  
  
  RESULTS
  There was no significant difference in IL-6 levels between a group receiving roxithromycin administration and a group not receiving roxithromycin. IL-1beta and TNF-alpha levels were significantly lower for the administration group after 7-14 days and after 21-28 days, respectively. However, a significant difference in bacterial counts in bone between the groups was not observed.
  
  
  CONCLUSIONS
  These results indicate that roxithromycin suppresses the local expression of IL-1beta and TNF-alpha, and may exhibit an anti-inflammatory effect in this osteomyelitis model.
authors.affiliation: Department of Dentistry, Hyogo Prefectural Staff Health Center, 5-10-1, Shimoyamate-dori, Chuo-ku, Kobe 650-8567, Japan. takashi3@basil.ocn.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshii
authors.forename: Shinya
authors.initials: S
authors.lastname: Magara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Miyai
authors.forename: Eiji
authors.initials: E
authors.lastname: Kuroki
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Nishimura
authors.forename: Shungo
authors.initials: S
authors.lastname: Furudoi
authors.forename: Takahide
authors.initials: T
authors.lastname: Komori
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D010019:Osteomyelitis / Q000188:drug therapy* / Q000378:metabolism; D015575:Roxithromycin / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000378:metabolism; D013211:Staphylococcus aureus / Q000187:drug effects; D013977:Tibia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
chemical_list: D016207:Cytokines; D015575:Roxithromycin